(Q35145033)

6 August 2017

1 reference

title

Review article: management of mild and severe gastro-oesophageal reflux disease (English)

1 reference

6 August 2017

1 reference

Tytgat GN

1

1 reference

PubMed ID

12786613

6 August 2017

language of work or name

English

0 references

publication date

1 June 2003

1 reference

Alimentary Pharmacology & Therapeutics

6 August 2017

1 reference

6 August 2017

17 Suppl 2

1 reference

6 August 2017

52-56

1 reference

Gastroesophageal reflux disease--should we adopt a new conceptual framework?

6 August 2017

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.17.S2.5.X

Effectiveness and safety of nizatidine, 75 mg, for the relief of episodic heartburn

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.17.S2.5.X

Synergy between low-dose ranitidine and antacid in decreasing gastric and oesophageal acidity and relieving meal-induced heartburn

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.17.S2.5.X

Management of heartburn in a large, randomized, community-based study: comparison of four therapeutic strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.17.S2.5.X

Treatment of gastroesophageal reflux disease: to step or not to step

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.17.S2.5.X

Lansoprazole 30 mg daily versus ranitidine 150 mg b.d. in the treatment of acid-related dyspepsia in general practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.17.S2.5.X

Lansoprazole compared with ranitidine for the treatment of nonerosive gastroesophageal reflux disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.17.S2.5.X

Treating the symptoms of gastro-oesophageal reflux disease: a double-blind comparison of omeprazole and cisapride.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.17.S2.5.X

Rabeprazole in nonerosive gastroesophageal reflux disease: a randomized placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.17.S2.5.X

On demand therapy with omeprazole for the long-term management of patients with heartburn without oesophagitis--a placebo-controlled randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.17.S2.5.X

Esomeprazole 20 mg maintains symptom control in endoscopy-negative gastro-oesophageal reflux disease: a controlled trial of 'on-demand' therapy for 6 months

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.17.S2.5.X

Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.17.S2.5.X

Meta-analysis of randomized controlled trials comparing standard clinical doses of omeprazole and lansoprazole in erosive oesophagitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.17.S2.5.X

Systematic review of proton pump inhibitors for the acute treatment of reflux oesophagitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.17.S2.5.X

Double-blind comparison [correction of Double-blind, placebo-controlled comparison] of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of erosive or ulcerative gastro-oesophageal reflux disease. The European Rabeprazole Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.17.S2.5.X

Rabeprazole, 20 mg once daily or 10 mg twice daily, is equivalent to omeprazole, 20 mg once daily, in the healing of erosive gastrooesophageal reflux disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.17.S2.5.X

Prognostic factors influencing relapse of oesophagitis during maintenance therapy with antisecretory drugs: a meta-analysis of long-term omeprazole trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.17.S2.5.X

The new proton pump inhibitor esomeprazole is effective as a maintenance therapy in GERD patients with healed erosive oesophagitis: a 6-month, randomized, double-blind, placebo-controlled study of efficacy and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.17.S2.5.X

Esomeprazole once daily for 6 months is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux disease symptoms: a randomized, double-blind, placebo-controlled study of efficacy and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.17.S2.5.X

Daily low-dose versus alternate day full-dose lansoprazole in the maintenance treatment of reflux esophagitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.17.S2.5.X

Bedtime H2 blockers improve nocturnal gastric acid control in GERD patients on proton pump inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.17.S2.5.X

In support of "step-up therapy" for gastroesophageal reflux disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.17.S2.5.X

Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.17.S2.5.X

Possibilities and shortcomings of maintenance therapy in gastroesophageal reflux disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.17.S2.5.X

10.1046/J.1365-2036.17.S2.5.X

21 January 2018

Identifiers

DOI

1 reference

6 August 2017

1 reference

PubMed ID

12786613